The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy,
critically depends on the activity of the host immune cells. However, various local and …

Despite significant advances in our knowledge regarding the genetics and molecular
biology of gliomas over the past two decades and hundreds of clinical trials, no effective …

Objectives: Immunostimulatory therapies using immune checkpoint blockers show clinical
activity in a subset of glioblastoma (GBM) patients. Several inhibitory mechanisms play a …

Introduction The overall survival in patients with gliomas has not significantly increased in
the modern era, despite advances such as immunotherapy. This is in part due to their …

Gliomas such as glioblastoma have a complex relationship with the immune system.
Glioblastomas have a harshly immunosuppressive microenvironment due in large part to the …

Inflammation is related to cancer. The systemic immune-inflammation index (SII) has been
linked to the prognosis of many types of cancer. The present study aimed to determine the …

Background. Systemic immunity and inflammation indexes (SI) derived from blood cells
have gained increasing attention in clinical oncology as potential biomarkers that are …

Glioblastoma (GBM) is the most common and lethal malignant tumor of the central nervous
system in adults. Conventional therapies, including surgery, radiotherapy, and …

Glioblastoma (GBM) is the most common primary brain tumor in adults an carries and carries
a terrible prognosis. The current regiment of surgical resection, radiation, and chemotherapy …

Glioblastoma multiforme (GBM) is the most malignant intracranial tumor in adults,
characterized by extensive infiltrative growth, high vascularization, and resistance to multiple …